<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346358</url>
  </required_header>
  <id_info>
    <org_study_id>14311</org_study_id>
    <secondary_id>CP24-1001</secondary_id>
    <secondary_id>I5F-IE-JSCA</secondary_id>
    <nct_id>NCT01346358</nct_id>
  </id_info>
  <brief_title>A Study of IMC-CS4 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose escalation study to establish the safety profile and characterize the pharmacokinetic
      profile of IMC-CS4 in the treatment of subjects with advanced solid tumors refractory to
      standard therapy or for which no standard therapy is available.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - Maximum concentration (Cmax) of IMC-CS4</measure>
    <time_frame>Up to Week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Minimum concentration (Cmin) of IMC-CS4</measure>
    <time_frame>Up to Week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Area Under the Curve (AUC) of IMC-CS4</measure>
    <time_frame>Up to Week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Volume of distribution at steady state (Vss) of IMC-CS4</measure>
    <time_frame>Up to Week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics -Clearance (Cl) of IMC-CS4</measure>
    <time_frame>Up to Week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommend Phase 2 Dose (RP2D) of IMC-CS4</measure>
    <time_frame>Approximately 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-IMC-CS4 Antibody Assessment</measure>
    <time_frame>Approximately 6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>IMC-CS4 Weight Based Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving IMC-CS4 intravenously (weight based dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-CS4 Non-Weight Based Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving IMC-CS4 intravenously (non-weight based dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-CS4</intervention_name>
    <arm_group_label>IMC-CS4 Weight Based Dosing</arm_group_label>
    <arm_group_label>IMC-CS4 Non-Weight Based Dosing</arm_group_label>
    <other_name>LY3022855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has histologic or cytologic confirmation of advanced solid tumors that is
             refractory to standard therapy or for which no standard therapy is available

          -  Subject has measurable or nonmeasurable disease according to Response Evaluation
             Criteria in Solid Tumors (RECIST) Version 1.1

          -  Subject has resolution to grade â‰¤1 by NCI-CTCAE (Common Toxicity Criteria for Adverse
             Effects) Version 4.03 of all clinically significant toxic effects of prior treatment

          -  Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Subject has adequate hematologic, hepatic, renal, and coagulation function

          -  Subject has a life expectancy greater than 3 months

          -  Subject agrees to use adequate contraception during the study period and for 12 weeks
             after last dose of study therapy

          -  Subject must undergo mandatory biopsies, including one pretreatment and one post
             treatment tumor biopsy procedure

        Exclusion Criteria:

          -  Subject has experienced acute pathologic fracture or spinal cord compression within 28
             days prior to first dose of study therapy

          -  Subject has a known hypersensitivity to monoclonal antibodies or to agents of similar
             biologic composition as IMC-CS4.

          -  Subject has received treatment with any monoclonal antibodies within 4 weeks prior to
             first dose of study therapy

          -  Subject has undergone a major surgical procedure, open biopsy, radiofrequency ablation
             or has experienced a significant injury within 28 days prior to enrollment

          -  Subject has a concurrent active malignancy other than adequately treated
             nonmelanomatous skin cancer or in situ neoplasm

          -  Subject has an ongoing or active infection, symptomatic congestive heart failure,
             uncontrolled hypertension, active bleeding or any other serious uncontrolled medical
             disorder

          -  Subject has known or suspected primary brain or leptomeningeal metastases

          -  Subject has leukemia or lymphoma

          -  Subject is know to have active tuberculosis, leishmaniasis, or listeriosis

          -  Subjects with known history, or clinical or laboratory evidence of liver disease

          -  Subject has a known active hepatitis B or C infection, Human immunodeficiency virus
             (HIV) infection or acquired immunodeficiency syndrome (AIDS)

          -  Subject if female, is pregnant or breastfeeding

          -  Subject has received an organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Angeles Clinic &amp; Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Phys &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

